Major Moves in UK Prostate Cancer Research: Screening, Fast-Track Diagnosis, and New Hope for Advanced Disease
Learn about the significance of UK prostate cancer screening and its role in addressing detection and treatment challenges.
Learn about the significance of UK prostate cancer screening and its role in addressing detection and treatment challenges.
Learn about the transformative role of AI in prostate cancer diagnosis, improving detection and consistency for better outcomes. Image for illustration only. People depicted are models.
Explore the FLEX-MRT trial for FLEX-MRT prostate cancer, evaluating a flexible dosing schedule for improved survival outcomes.
Discover how gozetotide changes prostate cancer diagnosis with improved accuracy and a focus on PSMA imaging technologies.
Discover how radioisotopes in medicine enhance diagnostics and treatments. Learn about their significance and uses today.
Modern prostate cancer treatment includes early detection, targeted therapies, and personalised care for improved patient outcomes and recovery.
Radiotheranostics and radiotherapeutics cancer treatments provide personalised care by combining diagnosis and targeted therapy.
Alpha particle emitting radionuclides are highly effective in delivering targeted radiation therapy for various cancers.
Radioactive isotopes emit targeted radiation that effectively destroys cancer cells while minimising harm to healthy tissues.
Thorium-227 Pelgifatamab utilises PSMA targeting and alpha emissions to destroy cancer cells while sparing healthy tissue effectively.
Terbium-161 PSMA-I&T combines precise PSMA targeting with beta and Auger emissions, revolutionising prostate cancer treatment efficacy.
Strontium-89 Chloride Therapy delivers targeted beta emissions to osteoblastic lesions, often reducing malignant bone pain substantially.
Tin-117m DTPA offers innovative treatment options for bone metastases, combining therapeutic efficacy with minimal collateral tissue damage.
Samarium-153 Lexidronam remains a reliable radiopharmaceutical delivering targeted beta radiation, alleviating painful metastases in suitable patients.
Rhenium-186 Etidronate, a radiopharmaceutical, delivers beta radiation to metastatic bone lesions, effectively reducing cancer-related pain.
Radium-223 Dichloride is a groundbreaking alpha-emitting radiopharmaceutical offering significant survival benefits for metastatic prostate cancer patients.
Lead-212 ADVC001 offers innovative alpha-emitting therapy, targeting PSMA-positive mCRPC with precise and potent tumour eradication.
Lutetium-177 XT033 combines PSMA targeting and Evans blue technology to improve metabolic stability and therapeutic effectiveness.
Lutetium-177 Rosopatamab is a radiopharmaceutical therapy combining targeted monoclonal antibodies with beta-emitting radioactive particles.
Lutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
Lutetium-177 PSMA-ALB-56 is an innovative treatment optimising prostate cancer therapy through targeted radiopharmaceutical advancements.
Lutetium-177 PNT2002 offers targeted radiotherapy for prostate cancer, combining precise tumour targeting with therapeutic and diagnostic capabilities.
Lutetium-177 Ludotadipep targets PSMA with enhanced stability, specificity, and reduced side-effects, revolutionising prostate cancer treatment.
Lutetium-177 iPSMA revolutionises prostate cancer treatment, delivering targeted beta radiation to metastatic cells with precision and minimal side effects.
Lutetium-177 EDTMP provides a cost-effective, accessible, and efficacious alternative for bone pain palliation in metastatic cancer patients.
Lutetium-177 EB-PSMA-617 represents an innovative radioligand therapy optimising tumour retention and therapeutic outcomes in metastatic prostate cancer.
Lutetium-177 DOTAZOL offers a dual-function approach, combining targeted radiotherapy and bone modulation, enhancing treatment for prostate cancer-related bone metastases.
Lutetium-177 DOTA-EB-TATE enhances neuroendocrine tumour therapy by improving tumour uptake, retention, and pharmacokinetics through albumin-binding Evans blue moieties.
Lutetium-177 CTT1403, an innovative PSMA-targeted therapy with irreversible phosphoramidate-based binding, shows remarkable efficacy in treating metastatic prostate cancer, enhancing tumour uptake, internalisation, and therapeutic precision.
Iodine-131 RPS-001, a radiolabelled small molecule targeting PSMA, shows promise in prostate cancer therapy through precision-directed beta radiation delivery.